Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Reexamination Certificate
2007-12-25
2007-12-25
Blanchard, David J. (Department: 1643)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
C530S387100, C530S387700, C530S388150, C424S130100, C424S133100, C424S141100
Reexamination Certificate
active
10377122
ABSTRACT:
The present invention provides humanized, chimeric and human anti-CD74 antibodies, CD74 antibody fusion proteins, immunoconjugates, vaccines and bispecific that bind to CD74, the major histocompatibility complex (MHC) class-II invariant chain, Ii, which is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies, other malignancies in which the cells are reactive with CD74, and autoimmune diseases, and methods of treatment and diagnosis.
REFERENCES:
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 5618920 (1997-04-01), Robinson et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 6051230 (2000-04-01), Thorpe et al.
patent: 2002/0018749 (2002-02-01), Hudson et al.
patent: WO 98/50435 (1998-11-01), None
patent: WO 00/67795 (2000-11-01), None
patent: WO 00/74718 (2000-12-01), None
Burgess et al, Journal of Cell Biology vol. 111 Nov. 1990 2129-2138.
Lazar et al Molecular and Cellular Biology Mar. 1988 vol. 8 No. 3 1247-1252.
Rudikoff et al (Proc. Natl. Acad. Sci. USA 1982 vol. 79 p. 1979).
Colman et al (Research in Immunology 1994, 145:33-36).
Ibragimova and Eade (Biophysical Journal, Oct. 1999, vol. 77, pp. 2191-2198).
Orlandi et al (Proc. Natl. Acad. Sci. USA, 86:3833-3837, 1989).
Hansen et al (Biochem. J. 1996, 320:293-300).
Shih et al (Cancer Immunol Immunother, 2000. 49:208-216).
Zhengxing Qu et al, “Internalization and Cytotoxic Effects of a Humanized Anti-CD74 Antibody, LL1”, Proceedings of the Annual Meeting of the American Association for Cancer Research, New York, NY, vol. 43, (2002), p. 255, XP001153818.
Mary M. Bendig, “Humanization of Rodent Monoclonal Antibodies by CDR Grafting”, Academic Press Inc., New York, NY, vol. 8, (1995), pp. 83-93, XP002943667.
Rita Ochakovskaya et al., Therapy of Disseminated B-Cell Lymphoma Xenografts in Severe Combined Immunodeficient Mice with an Anti-CD74 Antibody Conjugated with111Indium,67Gallium, or90Yttrium1, Clinical Cancer Research, U.S., vol. 7, No. 6, (2001) pp. 1505-1510, XP002255675.
P. Moller et al., “CD74”, Journal of Biological Regulatiors and Homeostatic Agents (2001), Italy, vol. 14, No. 4, (2000), pp. 299-301, XP009018091.
Oster, Wolfgang, et al., “Erythropoietin for the Treatment of Anemia of Malignancy Associated with Neoplastic Bone Marrow Infiltration” Journal of Clinical Oncology, vol. 8, No. 6 Jun. 1990: pp. 956-962.
Kolata, G., et al., “Clinical promise with new hormones” Science 236, 517 (1987); DOI: 10.1126/science.3495036.
Zhengxing, Qu, et al., Poster, “Internalization and Cytoitoixic Effects of a Humanized Anti-CD74 Antibody, LL1,” Annual Meeting of the American Association of Advancement of Cancer, Apr. 2002, San Francisco, CA.
Goldenberg David M.
Hansen Hans J.
Leung Shui-on
Qu Zhengxing
Blanchard David J.
Faegre & Benson LLP
Immunomedics Inc.
Nakashima Richard A.
Tungaturthi Parithosh K.
LandOfFree
Internalizing anti-CD74 antibodies and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Internalizing anti-CD74 antibodies and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Internalizing anti-CD74 antibodies and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3891250